Document type

Article

Version

Published version

Publication date

Publication license

cc by (c) Colini Baldeschi, Arianna et al., 2022
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/188742

Innovative Non-PrP-Targeted Drug Strategy Designed to Enhance Prion Clearance

Journal Title

Director/Tutor

Additional contribution

Journal ISSN

Volume Title

Abstract

Prion diseases are a group of neurodegenerative disorders characterized by the accumulation of misfolded prion protein (called PrPSc). Although conversion of the cellular prion protein (PrPC) to PrPSc is still not completely understood, most of the therapies developed until now are based on blocking this process. Here, we propose a new drug strategy aimed at clearing prions without any direct interaction with neither PrPC nor PrPSc. Starting from the recent discovery of SERPINA3/SerpinA3n upregulation during prion diseases, we have identified a small molecule, named compound 5 (ARN1468), inhibiting the function of these serpins and effectively reducing prion load in chronically infected cells. Although the low bioavailability of this compound does not allow in vivo studies in prion-infected mice, our strategy emerges as a novel and effective approach to the treatment of prion disease.

Subject (English)

Citation

Citation

COLINI BALDESCHI, Arianna, et al. Innovative Non-PrP-Targeted Drug Strategy Designed to Enhance Prion Clearance. Journal of Medicinal Chemistry. 2022. Vol. 65, num. 13, pags. 8998-9010. [consulted: 9 of October of 2026]. Available at: https://hdl.handle.net/2445/188742

Export metadata

JSON - METS

Share record